Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene editing
Biotech
Regeneron inks $150M pact with gene writer Tessera
The companies will jointly develop and commercialize Tessera's TSRA-196, a near-clinic candidate for alpha-1 antitrypsin deficiency (AATD).
Zoey Becker
Dec 1, 2025 11:12am
Scribe eyes clinic as CRISPR candidates lower lipids in animals
Nov 17, 2025 9:22am
FDA unveils new pathway to speed custom gene editing therapies
Nov 12, 2025 5:00pm
ARPA-H goes all in on in vivo cell therapy
Oct 8, 2025 4:04pm
Chiesi fertilizes Arbor's gene therapy with $2B biobucks deal
Oct 6, 2025 7:00am
ARPA-H unveils programs to develop custom gene editing therapies
Sep 26, 2025 10:41am
